Unknown PHASE1 INTERVENTIONAL 2-arm NCT04714294

Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

To Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study

Sponsor: Newsoara Biopharma Co., Ltd.

Conditions Healthy

Interventions HPP737 or placebo

Updated 6 times since 2021 Last updated: Jan 14, 2021 Started: Sep 8, 2020 Primary completion: May 31, 2021 Completion: May 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is ongoing. The trial is conducted by Newsoara Biopharma Co., Ltd. and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1
Dec 2025 — Jan 2026 [monthly]

Unknown PHASE1
Sep 2024 — Dec 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Feb 2021 — Jan 2023 [monthly]

Recruiting PHASE1

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Newsoara Biopharma Co., Ltd.

Data source: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China